Glooko vs Idexx Laboratories

Side-by-side comparison of AI visibility scores, market position, and capabilities

Glooko logo

Glooko

LeaderHealthcare

Digital Diabetes Management & Remote Patient Monitoring Platform

Glooko is a digital health platform for diabetes and chronic condition management; syncs data from 250+ glucose meters, CGMs, insulin pumps, and wearables; supports remote patient monitoring for clinicians and health systems; raised $100M+;

About

Glooko is a digital health company founded in 2010 and headquartered in Palo Alto, California, that provides a comprehensive platform for diabetes and chronic condition management. The company's technology aggregates data from over 250 connected diabetes devices — including continuous glucose monitors (CGMs), blood glucose meters, insulin pumps, pens, and health wearables — into a single unified platform that serves both patients and their care teams. For patients, Glooko provides a mobile app offering personalized insights, trend analysis, and education based on their glucose, insulin, activity, and nutrition data. For healthcare providers and clinical teams, Glooko's Population Health platform enables remote patient monitoring — allowing endocrinologists, diabetes educators, and primary care physicians to track patient cohorts, identify high-risk individuals, and deliver data-driven care interventions at scale.

Full profile
Idexx Laboratories logo

Idexx Laboratories

LeaderHealthcare Tech

Enterprise

Veterinary diagnostics leader with $3.81B FY2024 revenue; 130,000+ analyzer installed base; AI-powered inVue Dx digital cytology; VetConnect data platform; pet humanization tailwind.

AI VisibilityBeta
Overall Score
A94
Category Rank
#19 of 290
AI Consensus
71%
Trend
stable
Per Platform
ChatGPT
99
Perplexity
92
Gemini
88

About

IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headquartered. The company trades on Nasdaq (IDXX) and reported $3.81 billion in revenues for FY2024, maintaining its dominant position in point-of-care veterinary diagnostics through an installed base of over 130,000 Catalyst chemistry analyzers, ProCyte hematology systems, and SNAP rapid assay devices deployed in veterinary clinics worldwide. CEO Jay Mazelsky has continued IDEXX's expansion into AI-powered diagnostics and digital pathology, building on over four decades of veterinary-specific product development.

Full profile

Key Details

Category
Digital Diabetes Management & Remote Patient Monitoring Platform
Enterprise
Tier
Leader
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.